Innovagen

What Innovagen does

Innovagen AB is a privately held Swedish specialty biotech services and catalog reagents company founded in 1995 and headquartered in Lund, Sweden, with a staff of 1–10. It operates two complementary revenue lines: (i) custom service contracts covering the full antibody lifecycle — antigen generation, antibody development (monoclonal, polyclonal, anti-idiotypic, anti-drug antibodies), engineering (sequencing, humanization, isotype switching, Fc engineering, bispecifics, immunocytokines), modification (labeling, antibody-drug conjugates, fragmentation, glycosylation), production (recombinant via HEK293/CHO, hybridoma culture), and characterization — and (ii) a direct e-commerce catalog of off-the-shelf products including 412+ synthetic peptides, 65+ antibodies, 10 isotype controls, 6 biosimilar/analog therapeutic antibodies, and 5 recombinant proteins.

The underlying technology is wet-lab molecular biology: mammalian expression platforms (HEK293 and CHO cells) for recombinant antibody production across multiple isotypes and formats (hIgG1, hIgG4, mIgG2a, ScFv, BiTE), chromatographic purification (affinity, ion exchange, size exclusion), and solid-phase peptide synthesis with options for modifications, labeling, and stable-isotope incorporation. The company advertises a 3-week turnaround from sequence to recombinant antibody delivery and a self-positioned low price point for recombinant production.

Go-to-market is sales-led but executed through a direct, multi-currency e-commerce storefront (EUR, SEK, USD) with tiered unit pricing for catalog SKUs and quote-based pricing for custom services. Targeted customers are academic and institutional life science researchers, pharmaceutical and biotech companies engaged in therapeutic antibody development, and to a lesser extent diagnostic companies requiring validated reagents. Marketing presence is limited to the corporate website, LinkedIn, and Facebook — with no disclosed partnerships, distributors, or channel partners — and the firm holds no disclosed patents, awards, or regulatory certifications.

Name

Innovagen

Legal name

Innovagen AB

Website

https://innovagen.com

Company type

Private

Founded year

1995

Operating status

Operating

Headcount range

1–10 employees

Short description

Innovagen AB is a privately held Swedish specialty biotech founded in 1995 in Lund that sells an e-commerce catalog of 400+ synthetic peptides, antibodies, isotype controls, and recombinant proteins to academic and pharmaceutical researchers, and provides custom antibody and peptide services including development, engineering, modification, production, and characterization.

Ownership category

akta.pro rank

Product category

Biotech Research Reagents and Antibody Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industry

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

Keywords

• Antibody development services
• Synthetic peptide synthesis
• Recombinant protein production
• Antibody engineering services
• Biotech research reagents

Headquarters

HQ city

Lund

HQ country

Sweden

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Catalog Product Sales: Sale of off-the-shelf products including antibodies, synthetic peptides, recombinant proteins, isotype controls, and biosimilars/analogs. Products are sold in various quantities with tiered pricing.
2. Custom Service Contracts: Tailored research services including antigen generation, antibody development, antibody engineering, modification, production, and characterization. Services can be standalone or part of larger projects.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Innovagen provides tailored research products and services in molecular biology, specializing in antibody and peptide sciences. The company offers custom services spanning antigen generation, antibody development, engineering, modification, production, and characterization, alongside a catalog of synthetic peptides, recombinant proteins, primary antibodies, isotype controls, and biosimilar antibody analogs. Products and services are priced in EUR and serve academic, pharmaceutical, biotech, and diagnostic research customers globally.

Product overview

Innovagen is a specialized biotech services and products company offering a comprehensive portfolio in antibody and peptide sciences. The core offering consists of six interconnected service categories: Antibody Development (monoclonal, polyclonal, anti-idiotypic, ADA, antigen generation), Antibody Engineering (sequencing, humanization, isotype switching, Fc engineering, bispecifics, immunocytokines), Antibody Modification (labeling, ADC, fragmentation, glycosylation), Antibody Production (recombinant in HEK293/CHO cells, hybridoma culture, purification), Antibody Characterization (physico-chemical analysis, binding, effector function), and Peptides/Proteins (custom synthesis, recombinant production, modified/labeled peptides). The catalog products include 65+ antibodies (biosimilars like Trastuzumab/Pembrolizumab, isotype controls, primary antibodies), 412+ synthetic peptides (antimicrobial peptides, apelin, angiotensin, PAR agonists, TAT peptides), and 5 recombinant proteins (cKit, hST2, IL1RAP, PD-1, PDL-1). Services can be ordered standalone or integrated into larger custom projects.

Differentiator

Problem solved

Functional benefit

Products and services

• Antibody Development Services Tailored antibody development services including monoclonal antibodies, anti-idiotypic antibodies, anti-drug antibodies (ADA), polyclonal antibodies, and antigen generation for research and therapeutic applications.
• Antibody Engineering Services Specialized engineering services including antibody sequencing, isotype switching, humanization, Fc engineering, bispecific antibodies and other formats, and immunocytokines.
• Antibody Modification Services Modification services including antibody labeling, antibody drug conjugates (ADC), antibody fragmentation, and glycosylation modification.
• Antibody Production Services Production services including recombinant antibody production in HEK293/CHO cells, hybridoma cell culturing, and antibody purification using affinity chromatography, ion exchange, or size exclusion chromatography.
• Antibody Characterization Services Analysis services covering antibody physico-chemical properties, sequencing, binding characterization, and effector function evaluation.
• Peptides and Proteins Services Custom peptide synthesis, recombinant protein production, modified peptides, labeled peptides, stable isotope peptides, and catalog peptides.
• Synthetic Peptides (Catalog) Over 400 off-the-shelf synthetic peptides including antimicrobial peptides, apelin peptides, angiotensin peptides, bradykinin peptides, thrombin peptides (PAR agonists), HIV TAT peptides, and other research peptides for life science research applications.
• Recombinant Proteins (Catalog) Recombinant proteins including cKit (CD117), hST2 (IL1RL-1/IL33R), IL1RAP, PD-1, and PDL-1 expressed in mammalian cells with His/Fc tags for research use.
• Primary Antibodies (Catalog) Polyclonal primary antibodies targeting various proteins including CAP-18, LL-37, CRAMP, Dicer, Ghrelin, GPR40, HIV Tat, Menin, PITX2, and Wrap53 for research applications.
• Isotype Controls (Catalog) Isotype control antibodies including chimeric IgG1, hIgG1, hIgG1.LALA, IgG4.S228P, and polyclonal IgY/IgG from chicken, goat, and rabbit for use as experimental controls in antibody-based assays.
• Biosimilars and Analogs (Antibodies) Analog therapeutic antibodies including Atezolizumab, Blinatumomab, Canakinumab, Ivonescimab, Pembrolizumab, and Trastuzumab for research use as reference standards and assay reagents.

Quantifiable outcome

• 3-week turnaround from sequence to antibody delivery
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators5 records

Recent moves4 records

Expansion highlights5 records

Broad incumbents

• Bio-Techne (R&D Systems): Established life sciences tools company with deep antibody, recombinant protein, and peptide catalog serving the same academic and pharma researcher segment as Innovagen, with a much broader SKU base and global commercial reach.
• Abcam: Major antibody reagent supplier serving the same life-science researcher and pharma customer base; competes on catalog breadth, validation data, and brand trust against Innovagen's primary antibody and isotype control offerings.
• Novus Biologicals (Bio-Techne): Research antibody catalog and custom services supplier targeting life-science researchers, with comparable primary antibody, isotype control, and recombinant protein SKUs to Innovagen's catalog.
• Cell Signaling Technology: Specialized antibody producer with strong validation standards serving academic and pharma researchers; competes with Innovagen on primary antibody quality and reliability in the same customer segment.

Direct peers

• Creative Biolabs: Custom antibody services provider covering development, engineering (humanization, bispecifics, ADC), production, and characterization — a near direct competitor in Innovagen's core custom-service workflows.
• GenScript: Global biotech services company offering custom antibody development, engineering (humanization, bispecifics), recombinant protein production in HEK293/CHO, and peptide synthesis — directly overlapping Innovagen's full service and catalog portfolio at significantly larger scale.
• Rockland Immunochemicals: Antibody production and modification specialist (labeling, fragmentation, conjugation) serving research and diagnostic customers with overlapping capabilities to Innovagen's modification and custom production services.
• ProSci: Custom antibody and recombinant protein CRO offering polyclonal, monoclonal, and recombinant antibody production plus peptide services — overlapping Innovagen's antibody development and peptide offerings for pharma and academic clients.
• Sino Biological: Recombinant protein and antibody CRO with HEK293/CHO expression, custom antibody services, and a deep catalog of therapeutic antibody analogs — directly competing for the same pharmaceutical and academic customers.

Emerging players

• Bethyl Laboratories (Fortis Life Sciences): Specialty antibody producer focused on validated research antibodies with custom production capabilities; competes for the same academic and translational research budgets as Innovagen's catalog and custom services.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/profile.php?id=100063930104448
• LinkedInlinkedin.com/company/innovagen-ab

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Innovagen